Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Study Phase : Phase II/ Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Collaboration
Atom, CMS Partner on Lingdolinurad for Gout, Hyperuricemia Treatment
Details : The collaboration aims for the commercialization of ABP-671 (lingdolinurad), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia.
Product Name : ABP-671
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase II/ Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atom Bioscience Enrolling Patients In Global Phase 2b/3 Of Chronic Gout Treatment
Details : The company's primary product, ABP-671 a novel investigational orally administered URAT1 inhibitor, is currently undergoing Phase 2/3 clinical trials with patients for the treatment of chronic gout.
Product Name : ABP-671
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Study Phase : Phase II/ Phase III
Sponsor : Kaitai Capital
Deal Size : $83.0 million
Deal Type : Series D Financing
Details : The financing will be used for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout and to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and met...
Product Name : ABP-671
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase II/ Phase III
Sponsor : Kaitai Capital
Deal Size : $83.0 million
Deal Type : Series D Financing
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
Details : ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.
Product Name : ABP-671
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2023
Lead Product(s) : Lingdolinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapansutrile
Therapeutic Area : Rheumatology
Study Phase : Phase II/ Phase III
Sponsor : Sanders Morris Harris
Deal Size : $40.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used to advance OLT1177 (dapansutrile) into later stage clinical development. Dapansutrile is an investigational small molecule, that specifically binds to and blocks NLRP3, the sensor molecule integral in the formation of the NL...
Product Name : OLT1177
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2023
Lead Product(s) : Dapansutrile
Therapeutic Area : Rheumatology
Highest Development Status : Phase II/ Phase III
Sponsor : Sanders Morris Harris
Deal Size : $40.0 million
Deal Type : Series A Financing